{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T10:31:51Z","timestamp":1785407511715,"version":"3.56.0"},"reference-count":45,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Key Research and Development Program of China","award":["2023YFA0915703"],"award-info":[{"award-number":["2023YFA0915703"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82272890"],"award-info":[{"award-number":["82272890"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82203126"],"award-info":[{"award-number":["82203126"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"award":["82272890"],"award-info":[{"award-number":["82272890"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"publisher"}]},{"award":["82203126"],"award-info":[{"award-number":["82203126"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["2023TQ0390"],"award-info":[{"award-number":["2023TQ0390"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]},{"award":["2023TQ0390"],"award-info":[{"award-number":["2023TQ0390"]}],"id":[{"id":"https:\/\/ror.org\/0426zh255","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Young Talents Program of Sun Yat-sen University Cancer Center","award":["YTP-SYSUCC-0071"],"award-info":[{"award-number":["YTP-SYSUCC-0071"]}]},{"name":"Young Talents Program of Sun Yat-sen University Cancer Center","award":["YTP-SYSUCC-0077"],"award-info":[{"award-number":["YTP-SYSUCC-0077"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Most patients with hepatocellular carcinoma (HCC) present with advanced disease and have limited systemic treatment options. Oxaliplatin shows clinical activity in HCC but its effectiveness is frequently curtailed by intrinsic and acquired resistance. We sought to systematically identify genetic vulnerabilities that increase oxaliplatin sensitivity in HCC. Methods: Genome-scale negative-selection CRISPR\u2013Cas9 screens were conducted in two genetically distinct HCC cell lines (Hep3B and MHCC-97H) under low-dose oxaliplatin to discover conserved determinants of sensitivity. Selected DNA damage response (DDR) hits were validated. An oxaliplatin-resistant MHCC-97H subline was generated for transcriptomic profiling to characterize resistance-associated programs. Screen results were integrated with TCGA-LIHC expression and survival data to evaluate clinical relevance. Additionally, we analyzed bulk RNA-seq data from biopsy specimens collected from 36 HCC patients prior to initiation of hepatic arterial infusion chemotherapy (HAIC), comparing expression levels of the DDR genes between patients with objective response and non-responders. Results: Screens in both cell lines converged on DDR pathways, particularly nucleotide excision repair (NER) and the Fanconi anemia\/interstrand crosslink repair network; shared sensitizers included ERCC4 (XPF), FANCE and SLX4. Validation experiments showed that disruption of representative DDR factors (POLH and XPA) synergistically increased oxaliplatin efficacy at concentrations as low as 0.5 \u03bcM. Transcriptomic analysis of the resistant MHCC-97H subline revealed coordinated upregulation of DNA repair programs, G2\/M checkpoint and E2F target signatures, and epithelial\u2013mesenchymal transition features. Integration with TCGA-LIHC data demonstrated frequent overexpression of many screen-identified DDR genes in primary HCC and an association between higher expression of selected factors and poorer patient survival. In the HAIC cohort, several DDR genes, including ATR, BRCA2, CDK7, MUS81, MUTYH, PARG, POLH, POLK and XPA, were significantly lower in the objective response group. Conclusions: DDR components represent candidate biomarkers and therapeutic targets whose inhibition may enhance oxaliplatin efficacy in HCC.<\/jats:p>","DOI":"10.3390\/cancers18091360","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T14:28:23Z","timestamp":1777040903000},"page":"1360","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genome-Scale CRISPR Screens Reveal DNA Repair Dependencies That Sensitize Hepatocellular Carcinoma to Oxaliplatin"],"prefix":"10.3390","volume":"18","author":[{"given":"Hanyue","family":"Ouyang","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China"},{"name":"State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4660-6090","authenticated-orcid":false,"given":"Diyun","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China"},{"name":"State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China"},{"name":"State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lichang","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China"},{"name":"State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zichao","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China"},{"name":"State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhicheng","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China"},{"name":"State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minke","family":"He","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China"},{"name":"State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6035-3233","authenticated-orcid":false,"given":"Wenchao","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China"},{"name":"State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China"},{"name":"State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S228","DOI":"10.3350\/cmh.2024.0824","article-title":"Hepatocellular carcinoma: Updates on epidemiology, surveillance, diagnosis and treatment","volume":"31","author":"Hwang","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1158\/1078-0432.CCR-23-0060","article-title":"Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)","volume":"29","author":"He","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41571-021-00577-y","article-title":"FOLFOX-HAIC active in large HCC","volume":"19","author":"Sidaway","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41392-023-01663-6","article-title":"Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): A phase II study","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1200\/JCO.21.00608","article-title":"Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial","volume":"40","author":"Li","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1200\/JCO.21.01963","article-title":"Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1)","volume":"40","author":"Lyu","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jare.2025.02.016","article-title":"Comprehensive multi-omics analyses expose a precision therapy strategy that targets replication stress in hepatocellular carcinoma using WEE1 inhibition","volume":"78","author":"Jia","year":"2025","journal-title":"J. Adv. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12943-024-02101-z","article-title":"Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma","volume":"23","author":"Chan","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s13046-024-03134-4","article-title":"m6A-mediated lnc-OXAR promotes oxaliplatin resistance by enhancing Ku70 stability in non-alcoholic steatohepatitis-related hepatocellular carcinoma","volume":"43","author":"Lin","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"103869","DOI":"10.1016\/j.redox.2025.103869","article-title":"PARK7-driven IGF2BP3-K76 lactylation mediates ferroptosis and HAIC resistance in hepatocellular carcinoma","volume":"87","author":"Zhu","year":"2025","journal-title":"Redox Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"6738","DOI":"10.1038\/s41467-021-27099-6","article-title":"Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage","volume":"12","author":"Carotenuto","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2165\/00003495-200059004-00002","article-title":"Clinical perspectives on platinum resistance","volume":"59","author":"Giaccone","year":"2000","journal-title":"Drugs"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","article-title":"Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics","volume":"10","author":"Anand","year":"2023","journal-title":"Genes. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"9537","DOI":"10.1093\/nar\/gky764","article-title":"Base and nucleotide excision repair facilitate resolution of platinum drugs-induced transcription blockage","volume":"46","author":"Slyskova","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41568-020-00308-y","article-title":"The rediscovery of platinum-based cancer therapy","volume":"21","author":"Rottenberg","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.phrs.2016.01.001","article-title":"Cisplatin resistance and opportunities for precision medicine","volume":"106","author":"Amable","year":"2016","journal-title":"Pharmacol. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08467","article-title":"The DNA-damage response in human biology and disease","volume":"461","author":"Jackson","year":"2009","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6395","DOI":"10.1038\/s41388-021-02055-2","article-title":"A highly annotated database of genes associated with platinum resistance in cancer","volume":"40","author":"Huang","year":"2021","journal-title":"Oncogene"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1158\/1535-7163.MCT-05-0493","article-title":"Chemosensitization to cisplatin by inhibitors of the Fanconi anemia\/BRCA pathway","volume":"5","author":"Chirnomas","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/nature05976","article-title":"Replication and protection of telomeres","volume":"447","author":"Verdun","year":"2007","journal-title":"Nature"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1101\/gad.1214504","article-title":"Functional links between telomeres and proteins of the DNA-damage response","volume":"18","author":"Teo","year":"2004","journal-title":"Genes. Dev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.7545954","article-title":"A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1","volume":"266","author":"Miki","year":"1994","journal-title":"Science"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/378789a0","article-title":"Identification of the breast cancer susceptibility gene BRCA2","volume":"378","author":"Wooster","year":"1995","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer","volume":"22","author":"Telli","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature17676","article-title":"Landscape of somatic mutations in 560 breast cancer whole-genome sequences","volume":"534","author":"Davies","year":"2016","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ygyno.2018.08.030","article-title":"Nucleotide excision repair protein ERCC1 and tumour-infiltrating lymphocytes are potential biomarkers of neoadjuvant platinum resistance in high grade serous ovarian cancer","volume":"151","author":"Scurry","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3892\/ol.2016.4732","article-title":"High ERCC1 expression is associated with platinum-resistance, but not survival in patients with epithelial ovarian cancer","volume":"12","author":"Du","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Creeden, J.F., Nanavaty, N.S., Einloth, K.R., Gillman, C.E., Stanbery, L., Hamouda, D.M., Dworkin, L., and Nemunaitis, J. (2021). Homologous recombination proficiency in ovarian and breast cancer patients. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08863-9"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1038\/s41467-023-37537-2","article-title":"Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers","volume":"14","author":"Moser","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13048-023-01129-x","article-title":"Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma","volume":"16","author":"Feng","year":"2023","journal-title":"J. Ovarian Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ijc.20134","article-title":"Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines","volume":"110","author":"Welsh","year":"2004","journal-title":"Int. J. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.canlet.2012.05.009","article-title":"Cisplatin resistance induced in germ cell tumour cells is due to reduced susceptibility towards cell death but not to altered DNA damage induction or repair","volume":"324","author":"Fenske","year":"2012","journal-title":"Cancer Lett."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1200\/JCO.2016.68.7798","article-title":"Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors","volume":"34","author":"Bagrodia","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"215804","DOI":"10.1016\/j.canlet.2022.215804","article-title":"Mechanisms used by cancer cells to tolerate drug-induced replication stress","volume":"544","author":"Segeren","year":"2022","journal-title":"Cancer Lett."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s41580-024-00733-z","article-title":"Epithelial-mesenchymal transition in tissue repair and degeneration","volume":"25","author":"Youssef","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1186\/s12967-022-03776-y","article-title":"Platinum-resistance in epithelial ovarian cancer: An interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism","volume":"20","author":"Leung","year":"2022","journal-title":"J. Transl. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41418-024-01406-2","article-title":"METTL3 confers oxaliplatin resistance through the activation of G6PD-enhanced pentose phosphate pathway in hepatocellular carcinoma","volume":"32","author":"Jin","year":"2025","journal-title":"Cell Death Differ."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1200\/JCO.2016.67.5991","article-title":"Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors","volume":"34","author":"Leijen","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1158\/1078-0432.CCR-23-2409","article-title":"First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors","volume":"30","author":"Yap","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1038\/s41467-024-47215-6","article-title":"The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: A phase 2 trial","volume":"15","author":"Giudice","year":"2024","journal-title":"Nat Commun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.cell.2019.05.028","article-title":"A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy","volume":"178","author":"Wojtaszek","year":"2019","journal-title":"Cell"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/9\/1360\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T04:10:59Z","timestamp":1777176659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/9\/1360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":45,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["cancers18091360"],"URL":"https:\/\/doi.org\/10.3390\/cancers18091360","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]}}}